Literature DB >> 23020295

Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.

Christophe Morisseau1, Bruce D Hammock.   

Abstract

The presence of epoxyeicosatrienoic acids (EETs) in tissues and their metabolism by soluble epoxide hydrolase (sEH) to 1,2-diols were first reported 30 years ago. However, appreciation of their importance in cell biology and physiology has greatly accelerated over the past decade with the discovery of metabolically stable inhibitors of sEH, the commercial availability of EETs, and the development of analytical methods for the quantification of EETs and their diols. Numerous roles of EETs in regulatory biology now are clear, and the value of sEH inhibition in various animal models of disease has been demonstrated. Here, we review these results and discuss how the pharmacological stabilization of EETs and other natural epoxy-fatty acids could lead to possible disease therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23020295      PMCID: PMC3578707          DOI: 10.1146/annurev-pharmtox-011112-140244

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  133 in total

1.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

2.  Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.

Authors:  Dawn Chen; Randall Whitcomb; Euan MacIntyre; Vinh Tran; Zung N Do; James Sabry; Dinesh V Patel; Sampath K Anandan; Richard Gless; Heather K Webb
Journal:  J Clin Pharmacol       Date:  2011-03-21       Impact factor: 3.126

Review 3.  Soluble epoxide hydrolase inhibitors and heart failure.

Authors:  Hong Qiu; Ning Li; Jun-Yan Liu; Todd R Harris; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Cardiovasc Ther       Date:  2011-04       Impact factor: 3.023

4.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.

Authors:  Christophe Morisseau; Marvin H Goodrow; John W Newman; Craig E Wheelock; Deanna L Dowdy; Bruce D Hammock
Journal:  Biochem Pharmacol       Date:  2002-05-01       Impact factor: 5.858

Review 5.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 6.  Epoxyeicosatrienoic acid analogs and vascular function.

Authors:  V Sudhahar; S Shaw; J D Imig
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

7.  Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice.

Authors:  Ayala Luria; Steven M Weldon; Alisa K Kabcenell; Richard H Ingraham; Damian Matera; Huiping Jiang; Rajan Gill; Christophe Morisseau; John W Newman; Bruce D Hammock
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

8.  Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.

Authors:  Anne B Eldrup; Fariba Soleymanzadeh; Neil A Farrow; Alison Kukulka; Stéphane De Lombaert
Journal:  Bioorg Med Chem Lett       Date:  2009-11-22       Impact factor: 2.823

9.  Protein quaternary structure and expression levels contribute to peroxisomal-targeting-sequence-1-mediated peroxisomal import of human soluble epoxide hydrolase.

Authors:  Beibei Luo; Carol Norris; Erin S D Bolstad; David A Knecht; David F Grant
Journal:  J Mol Biol       Date:  2008-05-03       Impact factor: 5.469

Review 10.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

View more
  207 in total

1.  Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.

Authors:  Naoki Matsumoto; Eriko Suzuki; Makoto Ishikawa; Takumi Shirafuji; Keiji Hasumi
Journal:  J Biol Chem       Date:  2014-10-31       Impact factor: 5.157

2.  Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and inflammation in albumin-induced arthritis in temporomandibular joint of rats.

Authors:  Juliana Maia Teixeira; Henrique Ballassini Abdalla; Rosanna Tarkany Basting; Bruce D Hammock; Marcelo Henrique Napimoga; Juliana Trindade Clemente-Napimoga
Journal:  Int Immunopharmacol       Date:  2020-07-28       Impact factor: 4.932

3.  Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.

Authors:  Wanying Zhang; Haonan Li; Hua Dong; Jie Liao; Bruce D Hammock; Guang-Yu Yang
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

4.  Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation.

Authors:  Christophe Morisseau; Aaron T Wecksler; Catherine Deng; Hua Dong; Jun Yang; Kin Sing S Lee; Sean D Kodani; Bruce D Hammock
Journal:  J Lipid Res       Date:  2014-04-27       Impact factor: 5.922

5.  Treatment of mice with 2,3,7,8-Tetrachlorodibenzo-p-dioxin markedly increases the levels of a number of cytochrome P450 metabolites of omega-3 polyunsaturated fatty acids in the liver and lung.

Authors:  Jun Yang; Parrisa Solaimani; Hua Dong; Bruce Hammock; Oliver Hankinson
Journal:  J Toxicol Sci       Date:  2013       Impact factor: 2.196

Review 6.  The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.

Authors:  Sean D Kodani; Bruce D Hammock
Journal:  Drug Metab Dispos       Date:  2015-03-11       Impact factor: 3.922

Review 7.  Targeted lipidomic strategies for oxygenated metabolites of polyunsaturated fatty acids.

Authors:  Giuseppe Astarita; Alexandra C Kendall; Edward A Dennis; Anna Nicolaou
Journal:  Biochim Biophys Acta       Date:  2014-12-05

8.  1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, a Selective and Potent Dual Inhibitor of Soluble Epoxide Hydrolase and p38 Kinase Intervenes in Alzheimer's Signaling in Human Nerve Cells.

Authors:  Zhibin Liang; Bei Zhang; Meng Xu; Christophe Morisseau; Sung Hee Hwang; Bruce D Hammock; Qing X Li
Journal:  ACS Chem Neurosci       Date:  2019-08-19       Impact factor: 4.418

9.  Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage.

Authors:  Liang Dong; Yong Zhou; Zhao-Qiong Zhu; Tian Liu; Jia-Xi Duan; Jun Zhang; Ping Li; Bruce D Hammcok; Cha-Xiang Guan
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

10.  Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice.

Authors:  Yong Zhou; Tian Liu; Jia-Xi Duan; Ping Li; Guo-Ying Sun; Yong-Ping Liu; Jun Zhang; Liang Dong; Kin Sing Stephen Lee; Bruce D Hammock; Jian-Xin Jiang; Cha-Xiang Guan
Journal:  Shock       Date:  2017-05       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.